Publications by authors named "D Wilsmann-Theis"
Background: No currently approved treatment for pediatric plaque psoriasis selectively targets interleukin (IL)-23. In adults, guselkumab (a selective IL-23 inhibitor targeting the p19 subunit) demonstrated substantial efficacy with a favorable safety profile in treating moderate-to-severe plaque psoriasis.
Objective: PROTOSTAR (NCT03451851) evaluated the efficacy and safety of guselkumab in pediatric patients with moderate-to-severe plaque psoriasis.
Article Synopsis
- - Palmoplantar pustulosis (PPP) is a painful chronic skin disorder affecting the palms and soles, with no approved treatments in Europe and the USA, although guselkumab is approved in Japan.
- - A phase II study involving 50 Caucasian patients showed that administering 100 mg of guselkumab subcutaneously for 24 weeks significantly reduced the severity of PPP, with a median improvement of 59.6% in the PPP severity index.
- - The study concluded that guselkumab could be a viable treatment option for Caucasian patients suffering from moderate-to-severe PPP, as indicated by substantial improvements in both clinical and quality of life measures.
Background: Suboptimal influenza and pneumococcal vaccination rates have been reported before the COVID-19 pandemics in certain populations at risk for severe infection. The aim of this longitudinal cohort study was to investigate changes in influenza and pneumococcal vaccination rates and patient perceptions in patients with psoriasis (PsO) before and during the pandemic.
Methods: Data on vaccination, patient and disease characteristics, comorbidity, and patient perceptions were collected with questionnaires before and during the pandemic approximately one year later.
Article Synopsis
- Methotrexate (MTX) is an established long-term treatment for psoriasis vulgaris (PV), and this study aimed to evaluate its real-world effectiveness and safety over time.
- The study analyzed data from 55 patients over 247 patient-years, showing a 51.2% reduction in psoriasis severity (PASI) within the first six months, stabilizing afterward; side effects were generally mild.
- Results indicated no serious adverse events and suggested that low-dose MTX is both effective and safe for long-term therapy, though further investigation into higher-dose regimens is necessary for better efficacy data.